A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

NCT07165067 | Recruiting Phase 1

• 1 other identifier: AP601-101
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 3

Brief Summary

A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given safely. Participants will be assigned to one of six cohorts. Each cohort will receive a different dose of the study medication, AP601, based on the body weight. Each cohort will initially enrol 1-3 participants. If no serious side effects are seen in the first participant(s), the next cohort will receive the next dose level.

Conditions

Solid Tumours

Keywords

solid tumours; advanced or metastatic solid tumours; open label

Outcome Measures

Primary Outcomes (17)

• To determine the tolerability (MTD and/or maximum administered dose [MAD] of AP601 in patients with solid tumours.

  Estimate of the MTD based on DLTs observed during the DLT evaluation period.

  Initial 28 days from the first dose of AP601 which is Cycle1Day1 (each cycle is 14 days) until Cycle2Day14 (each cycle is 14 days)

• To determine the tolerability of Recommend Phase 2 Dose [RP2D])- MTD and/or maximum administered dose [MAD] of AP601 in patients with solid tumours.

  RP2D is based on the safety data - Estimate of the MTD based on DLTs observed during the DLT evaluation period

  TEAEs and SAEs will be assessed at Screening until 90-day safety follow up visit.

• To determine the tolerability of Recommend Phase 2 Dose [RP2D])

  RP2D tolerability is based on Pharmacokinetics data- blood samples will be collected to assess this.

  Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose (each cycle is 14 days), 0-6 hours, End of Trial Visit.

• To determine the tolerability of Recommend Phase 2 Dose [RP2D])

  RP2D tolerability is based on Pharmacodynamics data- blood samples will be collected to assess this

  PD will be assessed Cycle 1 - pre-dose, 24 hous, 72 hours, 168 hours. Cycle 2- pre-dose, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Pre-dose (each cycle is 14days) and at End of Trial Visit.

• To determine the tolerability of Recommend Phase 2 Dose [RP2D]

  Recommend Phase 2 Dose \[RP2D\] is based on antitumor activity data.

  Antitumour activity data will collected at End of Trial Visit , Safety Follow Up Visit (End of Trial + 30 days), Safety FUP Visit (End of Trial + 90 days) and at Survival Follow Up.

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (haematology)

  Haematology - blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

  Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle 3 Day1 to Cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit (EOT) and Safety Follow Up (EOT+ 30 days)

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (clinical chemistry)

  Clinical Chemistry- blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

  Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 until Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (Coagulation)

  Coagulation- blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

  Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 to last Cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (Thyroid Function tests )

  Thyroid Function tests - blood samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

  Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 - until last Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (EOT+ 30 days)

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in clinical laboratory parameters (urinalysis)

  Urine samples will be collected. All safety laboratory assessments will be assessed by a local laboratory according to their reference ranges.

  Assessed at Screening, Cycle1 Day1 , Cycle2 Day1, Cycle3 Day1 - until last Cycle 24 Day 1 (each cycle is of 14 days), End of Trial Visit and Safety FUP (End of Trial Visit+ 30 days)

• To determine the tolerability of RP2D - Number of Participants with a Change from baseline in Vital signs measurements Pulse rate [PR], systolic and diastolic blood pressure [BP], temperature and respiratory rate [RR]

  Blood pressure will be measured using a sphygmomanometer, body temperature will be measured using a thermometer, Heart rate (HR) is measured using vital sign machine, respiratory rate is measured manually via 60-second count \[RR\]. All abnormal assessments measured as Clinically significant post dose will be recorded as AEs.

  Assessed at Screening, Cycles 1 and 2 - Day 1, Day 2, Day 4, Day 8 Cycle 3 Day 1 - until last cycle 24 Day 1 (each cycle is 14 days), End of Trial Visit (EOT), Safety FUP (EOT + 30 days).

• To determine the tolerability of RP2D- Number of Participants with a Change from baseline in body weight

  Weight will be measured utilising scales.

  Assessed at Screening, Cycles 1 and 2 - Day 1, Day 2, Day 4, Day 8 Cycle 3 Day 1 - until last cycle 24 Day 1(each cycle is 14 days), End of Trial Visit(EOT), Safety FUP (EOT + 30 days).

• To determine the tolerability of RP2D- Change from baseline in Eastern Cooperative Oncology Group (ECOG) score

  Graded using a 6 point scale

  Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 up until last cycle 24 Day1 (each cycle is of 14 days), End of Trial Visit(EOT)and Safety FUP (EOT + 30 days) Visit.

• To determine the tolerability of RP2D- Change from baseline in measurements of HR in beats per minute

  12-lead ECG parameters include the measurements of HR in beats per minute. All ECGs will be performed in triplicate.

  Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial Visit(EOT) and Safety FUP (EOT + 30 days).

• To determine the tolerability of RP2D- Change from baseline in measurements of PR interval via 12-lead electrocardiogram

  12-lead ECG parameters include the measurements of PR interval. All ECGs will be performed in triplicate.

  Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT ) Visit and Safety FUP (EOT + 30 days).

• To determine the tolerability of RP2D- Change from baseline in measurements of QT interval via 12-lead electrocardiogram

  12-lead ECG parameters include measurements of QT duration. All ECGs will be in triplicate.

  Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT) Visit and Safety FUP (EOT + 30 days).

• To determine the tolerability of RP2D- Change from baseline in measurements of QRS duration via 12-lead electrocardiogram

  12-lead ECG parameters include the measurements of QRS duration. All 12-lead ECGs will be in triplicate.

  Assessed at Screening, Cycle1 Day1, Cycle2 Day1, Cycle3 Day1 until last cycle 24 Day 1(each cycle is of 14 days), End of Trial (EOT) Visit and Safety FUP (EOT + 30 days).

Secondary Outcomes (14)

• To assess the PK of AP601 in patients with solid tumours - Serum PK concentration of AP601.

  Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24 - Predose (each cycle is 14 days), 0-6 hours and End of Trial Visit.

• To assess the PK of AP601 in patients with solid tumours - Individual maximum concentration values, directly determined from the serum concentration time profiles for each participant (Cmax)

  Cycle 1 - pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cyle 24- Predose(each cycle is 14 days), 0-6 hours and End of Trial Visit.

• To assess the PK of AP601 in patients with solid tumours -Serum clearance following IV administration (CL)

  Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 -to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

• To assess the PK of AP601 in patients with solid tumours -Area under the serum concentration-time curve (AUC) from time zero to 168 hours post-dose (AUC0-168)

  Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24 hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24 Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

• To assess the PK of AP601 in patients with solid tumours - AUC from time zero to the last time point with measurable concentration using the linear trapezoidal rule (AUClast)

  Cycle 1 - Pre-dose, immediately following End of Infusion (EOI), 4 hours, 24hours, 72 hours, 168 hours. Cycle 2- pre-dose, EOI, 4 hours, 24hours, 72hours, 168hours, Cycle 3 to Cycle 24- Predose(each cycle is 14days), 0-6 hours and End of Trial Visit.

Study Arms (6)

Cohort 1

EXPERIMENTAL

Cohort 1: 0.5 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

Drug: AP601

Cohort 2

EXPERIMENTAL

Cohort 2: 1.25 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

Drug: AP601

Cohort 3

EXPERIMENTAL

Cohort 3: 2.5 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

Drug: AP601

Cohort 4

EXPERIMENTAL

Cohort 4: 5.0 mg/kg Participants will receive a single infusion of AP601 once every 2 weeks (14 days)

Drug: AP601

Cohort 5

EXPERIMENTAL

Cohort 5: 7.5 mg/kg

Drug: AP601

Cohort 6

EXPERIMENTAL

Cohort 6: 10.0 mg/kg

Drug: AP601

Interventions

AP601 DRUG

AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months. All doses of AP601 will be admistered intraveneously. The infusion time for all doses of AP601 in each patient will be approximately 60 to 120 minutes.

Cohort 1; Cohort 2; Cohort 3; Cohort 4; Cohort 5; Cohort 6

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Eastern Cooperative Oncology Group performance status of 0 to 1 at Screening, with an estimated life expectancy of at least 3 months.
• \. Disease must have at least 1 assessable (long diameter ≥1 cm) lesion for evaluation of response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
• \. Patients with adequate organ and bone marrow function, in the absence of growth factors, including the specific laboratory findings of Absolute neutophil count, platelet count, Haemoglobin, AST, ALT, Serum total Bilirubin, Alkaline phosphatase, prothrombin time, INR or activated partial thromboplastin time, creatinine and albumin.
• \. Female Volunteers must be of nonchild bearing potential i.e, surgically sterilised at least 6 weeks before Screening Visit or postmenopausal.
• \. Females of childbearing potential must have a negative pregnancy test, agree not to attempt to become pregnant or donate Ova and agree to use contraception from one month prior to Screening until at least 90 days after last dose of study drug, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.
• Male Vonuteers:
• Must agree not to donate sperm from signing the ICF until at aleast 90 days after the last dose of the study drug.
• If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception.
• Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

You may not qualify if:

• Has received concurrent antitumor treatment or IPs within 28 days of C1D1. The antitumor treatments include chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormonal therapy, or cytokine therapy.
• Has received prior CD73-targeted and/or CD137-targeted therapeutics.
• Has had major surgery within 28 days prior to C1D1 (excluding prior diagnostic biopsy).
• Any unresolved toxicity (except alopecia) from prior therapy of ≥CTCAE Grade 1, prior to the day of the first dose of IP. Participants with Grade 2 toxicity that is not CS (e.g., alopecia, vitiligo), or that is deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled.
• History of any other malignancy, which has been active or treated within the past 2 years, with the exception of thyroid cancer, cervical intraepithelial neoplasia, basal cell carcinoma and squamous cell carcinoma.
• Prior history of an irAE with immunotherapy-related toxicities that resulted in discontinuation of prior immunotherapy.
• Current symptomatic leptomeningeal disease or uncontrolled, untreated brain metastasis.
• Has received any organ transplantation including allogeneic stem cell transplantation.
• Has received blood transfusions or growth factor support ≤ 14 days prior to screening.
• Has any significant acute or chronic infections including:
• Infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before first dose of AP601.
• Known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
• Current active, or history of, any autoimmune disease that may relapse or immunodeficiencies.
• Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before first dose of AP601.
• Known severe hypersensitivity reactions to monoclonal antibodies.

Sponsors & Collaborators

• AP Biosciences Inc.: lead
• Avance Clinical Pty Ltd.: collaborator

Study Sites (3)

Calvary Mater Newcastle

Waratah, New South Wales, 2298, Australia

NOT YET RECRUITING

Pindara Private Hospital

Brisbane, Queensland, 4217, Australia

NOT YET RECRUITING

Epworth HealthCare

Melbourne, Victoria, 3121, Australia

RECRUITING

Central Study Contacts

Grace Lu

CONTACT

886-2-2653-2886; cwlu@apbioinc.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Masking Details: Open Label study
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. AP601 represents an innovative therapeutic approach, targeting both CD73 and CD137 to synergistically enhance antitumour immunity through two synergistic mechanisms. CD73, an ecto-enzyme frequently overexpressed in various cancers, plays a pivotal role in immune suppression by converting adenosine monophosphate into adenosine, which suppresses T cell activity within the tumour microenvironment (TME). By inhibiting CD73, AP601 mitigates adenosine-mediated immunosuppression, fostering a more effective immune response. Simultaneously, AP601 targets CD137, a key costimulatory receptor on activated T cells and natural killer cells. Engagement of CD137 stimulates proliferation and enhances the cytotoxic function of these immune cells. AP601's dual-targeting design restricts CD137 activation to the TME. This targeted approach minimizes systemic toxicity and enhances therapeutic specificity.

Study Record Dates

• First Submitted: August 20, 2025
• First Posted: September 10, 2025
• Study Start: January 21, 2026
• Primary Completion (Estimated): December 27, 2027
• Study Completion (Estimated): January 30, 2028
• Last Updated: December 29, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

AU (3)